When There Is No Approved Treatment: The Race to Deploy Mapp Bio's Experimental Ebola Antibody

The WHO has declared the Bundibugyo Ebola outbreak a global health emergency. With no approved treatments, the US government has turned to a small San Diego biotech and its experimental antibody MBP134. The story reveals a structural gap in how the world prepares for infectious disease.

Ozempic Doesn't Work for Every Form of Obesity. Palatin Technologies Is Targeting the Patients It Misses.

Most people at this point have heard of Ozempic. Far fewer have heard of the patients it does not help. For a meaningful subset of obese patients, GLP-1 drugs simply do not work, because the appetite circuit in their brain is broken in a way GLP-1 mechanisms cannot fix. Palatin

The Hormone Nobody Talked About: How Baxfendy Just Opened a New Front in the War on Hypertension

AstraZeneca's Baxfendy (baxdrostat) is the first aldosterone synthase inhibitor approved by the FDA, offering a fundamentally new approach to treating resistant hypertension in the 23 million Americans whose blood pressure remains uncontrolled despite multiple medications.

Forty Years in the Making: How Three Competing Technologies Are Finally Challenging Alpha-1 Antitrypsin Deficiency

Three competing technologies—from Sanofi, Wave Life Sciences, and Beam Therapeutics—are finally challenging Alpha-1 Antitrypsin Deficiency after four decades of limited treatment options.

After a $197M BARDA Deal for NexoBrid, MediWound Just Got Europe's Attention (NASDAQ: MDWD)

MediWound Ltd. (Nasdaq: MDWD) recently earned a spot in one of Europe's most exclusive health security forums, and the timing could not be more relevant.

The p-Value That Wasn't: What Regeneron's Fianlimab Miss Reveals About the Limits of Dual Checkpoint Blockade in Melanoma

Regeneron's Phase 3 HARMONY trial of fianlimab plus cemiplimab missed statistical significance in melanoma despite a 5.1-month PFS improvement. What the p-value of 0.0627 reveals about dual checkpoint blockade.

The Cisplatin Gap Closes: AstraZeneca's VOLGA Trial Rewrites the Standard of Care for Bladder Cancer

AstraZeneca's VOLGA Phase 3 trial delivers a statistically significant overall survival benefit for cisplatin-ineligible muscle-invasive bladder cancer patients, marking a turning point for a population that has long been underserved by perioperative treatment options.

After Makary: What the FDA's Leadership Vacuum Means for Drug Development

Marty Makary's sudden resignation as FDA commissioner leaves the pharmaceutical industry facing regulatory uncertainty at a critical moment for biotech recovery.

The Pill That Changed Everything: FDA Approves First All-Oral AML Regimen for Elderly Patients

The FDA approves Inqovi in combination with venetoclax as the first all-oral treatment for elderly patients with newly diagnosed AML, eliminating the need for frequent infusion center visits.

The Promise That Couldn't Scale: What Sarepta's Elevidys Decline Reveals About Gene Therapy's Commercial Ceiling

Sarepta's Elevidys gene therapy beats revenue estimates but faces declining sales, revealing the gap between clinical promise and commercial durability in the gene therapy sector.

No Antibody, No Problem: How argenx Just Rewrote the Rules for Myasthenia Gravis Treatment

argenx's VYVGART receives FDA approval for all generalized myasthenia gravis patients regardless of serotype, including the triple seronegative population previously excluded from treatment options.

The Slide That Sees Everything: What Roche's $1 Billion PathAI Bet Reveals About the Future of Cancer Diagnosis

Roche's $1.05 billion acquisition of PathAI signals that AI-powered digital pathology is becoming as strategically important as drug development itself in precision oncology.